12,372 trials
Primary Immunodeficiency Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs — 12; 3; 12 Participants
Diabetic Neuropathy, Painful
Primary: Efficacy of Engensis Compared to Placebo Painful Diabetic Peripheral Neuropathy in Feet and Lower Legs Comparing Average Daily Pain Score From Day 0 Visit to Day 180…
Chronic Hand Eczema
Primary: Number of Treatment-emergent Adverse Events From Baseline up to Week 38 — 1238 events
Immune Thrombocytopenia
Primary: Durable Platelet Response — 15; 0 Participants — p=0.0077
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) — -1.40; -0.86 Percentage point of HbA1c — p=<0.0001
Diabetic Peripheral Neuropathy
Primary: To Evaluate the Efficacy of Intramuscular Administration of Engensis on Reducing Pain in Participants With Painful Diabetic Peripheral Neuropathy in the Feet and Lower…
Ulcerative Colitis (UC)
Primary: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score — 1; 7; 6; 6 Participants — p=0.0324
Moderate to Severe Midface Volume Deficit
Primary: The Percentage of Responders on the 5-point Mid-Face Volume Deficit Severity Scale (MVDSS) at Week 24 - Per Protocol Dataset — 268; 124 Participants — p=<0.0001
Atopic Dermatitis
Primary: Number of Adverse Events From Baseline Through the Last Treatment Visit (up to Week 268) — 8119 events
Seasonal Influenza
Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) — 5620; 7989; 3840; 4433 Participants
Intravenous Administration
Primary: Pain Score Based on Wong-Baker Pain Scale During IV Placement With Buzzy Bee or Vapocoolent — 4.54; 5.41; 5.03; 3.84 units on a scale
Growth Hormone Deficiency · Endocrine System Diseases · Hormone Deficiency
Primary: Change From Baseline in Trunk Percent Fat at Week 38 — -1.68; 0.37 percent fat — p=<.0001
Anemia Associated With Chronic Kidney Disease (CKD)
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26) — -0.07; 0.14; 0.36 Grams per deciliter (g/dL)
Overweight and Obesity
Primary: Weight Change (Percent of Initial Body Weight) From Baseline to Month 12, Main Effect of Time — -5.8 percent of initial body weight — p=<.001
Peripheral Artery Disease
Primary: Six-minute Walk Distance (NR Alone vs. Placebo) — -6.93; 7.00; -10.58 meters — p=0.0775